making moves

Houston female-health focused tech company makes 2 key acquisitions

FemTec Health has acquired two companies — a women's reproductive platform and a nutrition platform. Image via avawomen.com

Last month, a Houston-based, tech-enabled health and beauty sciences company made two acquisitions of startups in the femtech space.

FemTec Health, creator of the Awesome Woman comprehensive health care subscription platform, has acquired Ava AG — a women's reproductive digital diagnostics and therapeutics company — and Nutrimedy — a clinical nutrition platform.

Ava, founded by Lea von Bidder in Zurich in 2014, uses artificial intelligence and clinical trials-backed science to help women conceive faster. Per a news release, the FDA-cleared technology has helped over 70,000 women get pregnant.

"What Lea and the Ava team have built is truly innovative. We are excited to add the leader in reproductive health to our portfolio and onto our team," says Dr. Kimon Angelides, FemTec Health founder and CEO, in the July 19 release. "From fertility to contraception, pregnancy support, menopause management, and personalized health insights, Ava's technology is a great addition to make it even easier for women within the FemTec Health platform to take control of their health, all while keeping their data and personal health information one hundred percent private and secure."

FemTec Health's Awesome Woman platform will integrate Ava's technology, adding reproductive health to its list of female-focused health care services which includes vaginal health, hormone balance, sexual wellness, and beauty.

"Ava's vision has always been to be a companion to women along every stage of their lives. With Ava's female health AI integrated into FemTec's care platform, women will finally have access to a fully continuous health journey," says von Bidder in the release. "We are excited to join FemTec in building continuous support for women from puberty to menopause."

Last week, FemTec announced the acquisition of Nutrimedy, a HIPAA-compliant digital health platform founded by Karolina Starczak in Boston in 2016. With the acquisition, Awesome Women members will have access to Nutrimedy's guided nutritional support.

"For many health conditions, nutrition is a key but often neglected component," says Angelides, in the July 25 news release. "Adding Nutrimedy's robust, evidence-based clinical nutrition platform to the Awesome Woman program will be a gamechanger for our subscribers. Whether it's to optimize pregnancy planning, manage menopause symptoms, or for general wellness and prevention, research shows women are seeking personalized, science-backed nutritional support that's easy to use and that they can trust."

With its AI-powered platform, users can access real-time food recommendations and photo food logging. Nutrimedy empowers those suffering from chronic conditions and disruptive food allergies and sensitivities, to make informed dietary decisions in the moment.

"Nutrimedy was started with the mission to improve access to nutrition in healthcare and make it significantly more personalized and actionable in our hectic daily routines," says Starczak in the release. "Within the field of nutrition, conflicting and confusing misinformation is pervasive and prevents most people from making the best decision for their individual health."

Last fall, FemTec Health emerged from stealth with $35 million in fresh VC investment. The company has also acquired Birchbox, Mira Beauty, and Liquid Grids over the past year.

Angelides, a Houstonian, previously told InnovationMap that he was driven to found FemTech Health because there was no holistic platform focused on every phase of women's health.

"Women don't really have a program that's designed for them," Angelides says on the Houston Innovators Podcast. "We embarked in terms of building a platform and a company that would be a single destination for women — one that's not age specific but built around journeys."

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted